web logo
  • Therapies
    • DNX-2401
    • Combination Therapies
  • Diseases
    • Adult Brain Cancer
    • Pediatric Brain Cancer
  • Clinical Trials
    • Pediatric Clinical Trials
    • Adult Clinical Trials
    • Compassionate Use
  • Company
    • Management Team
    • Board of Directors
    • Key Advisors
    • Clinical Partners
  • Investor Resources
    • Company News & Presentations
    • Scientific Publications
    • Investor Presentations
  • Contact

News

A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases

Purpose: To determine the maximum tolerated dose (MTD), toxicity spectrum, clinical activity, and biological effects…

Read more

Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients

There are no effective treatments for diffuse intrinsic pontine gliomas (DIPGs); these tumors cannot be…

Read more

Oncolytic Virotherapy for Malignant Gliomas

The following represents disclosure information provided by authors of this manuscript. All relationships are considered…

Read more

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus. Preclinical studies demonstrated antiglioma efficacy, but…

Read more

Infectious enthusiasm

How oncolytic viruses are coming of age in cancer immunotherapy combinations After over two decades…

Read more

DNX-2401 wins $2 million FDA grant for cancer immunotherapy

DNX-2401 has won a $2 million grant from the Food and Drug Administration to support…

Read more

Potential of oncolytic viruses back on industry’s radar screen

Research on the potential of oncolytic viruses to treat various cancer types has waxed and…

Read more

A cold virus could extend lives of some brain cancer patients, MD Anderson study finds

A genetically engineered cold virus that attacks tumor cells and triggers an immune response significantly…

Read more

Smart bomb virus shows promise as brain tumor immunotherapy

A common cold virus engineered to attack the most common and deadly of brain tumors…

Read more
  • <
  • 1
  • 2
  • 3
  • >
footer-logo
  • Address

    3400 Edloe Street, Suite 335 Houston, TX 77027

Therapies
  • DNX-2401 (tasadenoturev)
  • Combination Therapies
Diseases
  • Adult Brain Cancer
  • Pediatric Brain Cancer
Science
  • Pediatric Clinical Trials
  • Adult Clinical Trials
Company
  • Management Team
  • Board of Directors
  • Clinical Partners
Contact
  • Terms of Use Policy
  • Privacy Policy

Copyright © 2026. CVBio. All Rights Reserved